301: Biotech mega-rounds, a cancer vaccine se...

How was a known friend of Jeffrey Epstein able to raise $100 million, with the help of a prominent biotech VC? And will Vinay Prasad return to the Food and Drug Administration for a "three-peat"? Damian Garde joins Allison, Adam, and Elaine to discuss his article about Boris Niko ...  Show more

Will drugmakers finally be able to breach the efficacy ceiling in inflammatory bowel disease? And is the Food and Drug Administration being flexible enough with rare disease treatments? Spyre Therapeutics CEO Cameron Turtle joins the podcast to discuss his company's experimental ...  Show more

In this cross-over episode from Bio Eats World, Kristen Fortney, cofounder and CEO of BioAge, joins Vijay Pande, founding partner of a16z Bio + Health, and Olivia Webb, editorial lead, to discuss the biology of aging, how she started a company, and some fun things — like how l ...

Join us this week in The Deal Room as we dissect the buzz surrounding Google's potential acquisition of HubSpot, a deal potentially valued at a $35bn. Discover the strategic reasoning behind it, potential synergies, and the looming antitrust hurdles.

We also take you ...

You’ve heard data has the power to make or break a business. Nobody knows this more than Anne Wojcicki, co-founder of biotech giant 23andMe. After 15 years of leveraging data to build a game-changing company, Wojcicki made headlines this summer when she became the latest self-mad ...  Show more

In this episode, Peter and Salim take a deep dive into Exponential Organizations and how experimentation can help exponentially build a business.  You will learn about: 02:52 | The New School Is Surpassing The Old School. 18:50 | Trial & Error Will Give You The Data N ...  Show more